Carcinoma, Non-Small-Cell Lung Clinical Trial
— BaliseOfficial title:
A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib
Verified date | February 2024 |
Source | Eli Lilly and Company |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of this study is to compare the efficacy of the study drug LY2875358, given together with erlotinib, against erlotinib, alone. Participants will have Non-Small Cell Lung Cancer (NSCLC) that has advanced to Stage IV. Participants should not have been treated with drugs for Stage IV NSCLC, previously. All participants will get erlotinib alone, for approximately 8 weeks. Participants with radiographic disease control at the end of the erlotinib lead-in study period will be randomly assigned to receive LY2875358 plus erlotinib or erlotinib alone. Participants, who were chosen to receive erlotinib, alone, may cross over to the combination treatment at the time of progression.
Status | Active, not recruiting |
Enrollment | 150 |
Est. completion date | December 31, 2024 |
Est. primary completion date | March 14, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of metastatic Stage IV NSCLC - Have at least 1 measurable lesion whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) - Have molecular evidence of an epidermal growth factor receptor mutation (EGFRmt) known to be associated with EGFR tyrosine kinase inhibitor (TKI) drug sensitivity (G719X, exon 19 deletion, L858R, L861Q) - Eastern Cooperative Oncology Group (ECOG) performance status of = 2 - Haven't received any prior systemic chemotherapy for Stage IV NSCLC (unless received as neoadjuvant or adjuvant therapy for early-stage NSCLC disease and completed therapy at least 6 months prior to enrollment) - Availability of adequate tumor material (block or slides) Exclusion Criteria: - Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device - Have previously completed or withdrawn from this study or any other study investigating LY2875358 - Have a serious concomitant systemic disorder or significant cardiac disease - Have interstitial pneumonia or interstitial fibrosis of the lung or have pleural effusion, pericardial fluids or ascites, requiring drainage every other week or more frequently - Have a history of another malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years prior to the study - Have major surgery less than 2 weeks prior to the initiation of study treatment therapy - Pregnant or lactating women |
Country | Name | City | State |
---|---|---|---|
Denmark | Herlev and Gentofte Hospital | Herlev | Hovedstaden |
Denmark | Rigshospitalet | Kobenhavn | Copenhagen |
Denmark | Odense Universitetshospital | Odense C | Syd |
France | CHU de Caen Hopital Cote de Nacre | Caen | |
France | Chu Gabriel Montpied | Clermont-Ferrand | |
France | CHU De Grenoble Hopital Albert Michallon | Grenoble Cedex 09 | |
France | HCL-Hôpital Louis Pradel | Lyon (Bron) Cedex | |
France | Hôpital Arnaud de Villeneuve - CHU Montpellier | Montpellier Cedex 5 | |
France | CHU la Miletrie | Poitiers | |
Germany | Helios Klinikum Emil von Behring Berlin-Zehlendorf | Berlin | |
Germany | Klinik Schillerhöhe | Gerlingen | Baden-Württemberg |
Germany | Thoraxklinik-Heidelberg gGmbH | Heidelberg | Baden-Württemberg |
Germany | Klinikum Köln-Merheim | Köln | Nordrhein-Westfalen |
Germany | Universitätsklinikum Schleswig-Holstein | Lübeck | Schleswig-Holstein |
Germany | Universitätsklinikum Ulm | Ulm | Baden-Württemberg |
Italy | Istituto Tumori ""Giovanni Paolo II | Bari | |
Italy | Istituti Ospedalieri di Cremona | Cremona | |
Italy | Azienda Ospedaliera Universitaria Careggi | Firenze | Florence |
Italy | Azienda Sanitaria Ospedaliera S Luigi Gonzaga | Orbassano | Torino |
Italy | Istituto Oncologico Veneto IRCCS | Padova | Veneto |
Korea, Republic of | Chungbuk National University Hospital | Cheongju-si | Chungcheongbuk-do [Chungbuk] |
Korea, Republic of | Gachon University Gil Medical Center | Namdong-gu | Incheon-gwangyeoksi [Incheon] |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | Kyonggi-do |
Korea, Republic of | Asan Medical Center | Seoul | Seoul-teukbyeolsi [Seoul] |
Korea, Republic of | Samsung Medical Center | Seoul | Seoul-teukbyeolsi [Seoul] |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul | Korea |
Korea, Republic of | Ulsan University Hospital | Ulsan | Ulsan-Kwangyokshi |
Netherlands | Ziekenhuis Rijnstate | Arnhem | |
Netherlands | Jeroen Bosch Hospital | Den Bosch | Noord-Brabant |
Netherlands | Ziekenhuis St. Jansdal | Harderwijk | |
Netherlands | St. Antonius Ziekenhuis, locatie Nieuwegein | Nieuwegein | |
Spain | Hospital del Mar | Barcelona | |
Spain | Hospital Puerta De Hierro | Majadahonda | Madrid |
Spain | Clinica Universitaria De Navarra | Pamplona | Navarra |
Spain | Hospital Universitario Quironsalud Madrid | Pozuelo de Alarcon | Madrid |
Spain | Corporacion Sanitaria Parc Tauli | Sabadell | Barcelona |
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | Taichung Veterans General Hospital | Taichung | |
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei | |
United Kingdom | Charing Cross Hospital | Chelsea | London |
United Kingdom | Gartnavel General Hospital | Glasgow | Glasgow City |
United Kingdom | Churchill Hospital | Oxford | |
United Kingdom | New Cross Hospital | Wolverhampton | West Midlands |
United Kingdom | Wythenshawe Hospital | Wythenshawe | Manchester |
Lead Sponsor | Collaborator |
---|---|
Eli Lilly and Company |
Denmark, France, Germany, Italy, Korea, Republic of, Netherlands, Spain, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival (PFS) | Randomization to Objective Disease Progression or Death Due to Any Cause (Estimated 3 Years) | ||
Secondary | Change in Tumor Size (CTS) | Baseline to Measurement with Smallest Tumor Size (Estimated 3 Years) | ||
Secondary | Proportion of Participants Exhibiting a Confirmed Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) | Baseline to Objective Disease Progression or Start of New Anticancer Therapy (Estimated 3 Years) | ||
Secondary | Duration of Response (DoR) | Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated 3 Years) | ||
Secondary | Time to Progressive Disease (TTPD) | Randomization to Objective Disease Progression (Estimated 3 Years) | ||
Secondary | Proportion of Participants Exhibiting a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate [DCR]) | Baseline to Objective Disease Progression or Participant Stops Study (Estimated 3 Years) | ||
Secondary | Overall Survival (OS) | Randomization to Death Due to Any Cause (Estimated 5 Years) | ||
Secondary | Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ) C30 (QLQ-C30) and Lung Cancer 13 (QLQ-LC13) | Baseline, Objective Disease Progression or Participants Stops Study (Estimated 3 Years) | ||
Secondary | Pharmacokinetics (PK): Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) of LY2875358 and Erlotinib | Baseline through Cycle 4 (28 Day Cycle) | ||
Secondary | Proportion of Participants with Anti-LY2875358 Antibody Response | Baseline through 30 Day Follow Up (Estimated 3 Years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |